Currently, Carmen Peralta is IDIBAPS Researcher group leader Experimental Liver Surgery and Liver transplantation, and coordinator of the Consolidated Research Group for the Generalitat of Catalonia (Group for Quality in Research). The research carried out by Carmen Peralta is focused on pharmacological and surgical strategies that protect steatotic and non-steatotic livers against the vulnerability of this type of liver to ischemia-reperfusion injury and regeneration failure associated with hepatic resections and liver transplantation. Protective strategies in reduced-size liver transplantation are also investigated. Our research could improve the postsurgical outcome in liver surgery and could also contribute to a better use of organs for transplantation and consequently, to diminish waiting lists for liver transplantation.
Carmen Peralta received her Ph.D degrees in Health Sciences and has published more than 102 research articles in international journals with high impact factor in the speciality of Organ Transplantation, and the most of them as first or last author. The average impact factor per publication is 8. Carmen Peralta is above the average of citations at international level in the field of liver transplantation and has an H index of 36 in 21 years of research career. She is the inventor of different patents related with organ transplantation and surgery. Carmen Peralta has participated in more than 150 national and international congresses related with organ transplant and is evaluator of research projects and editorial member of international journals related with organ transplantation. In addition, she has participated and participates as leader or partner in 50 national and international projects funded in public calls and research contracts with companies in organ transplantation.
11:15 - 13:15
|Post-Graduate Course — Basic Science: Innate Immune Response & Microbiome||Inflammasome-mediated inflammation||N-103|
11:45 - 13:15
|Plenary — Plenary Session 1 -Improving Patient Outcomes - Organ Donation||Molecular therapeutic targets to minimise ischemia reperfusion injury||Hall 10 - Plenary|